related documents
- A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma. Conferences
- A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCICCTG IND. 154. Conferences
- A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). Conferences
- A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial Conferences
- A phase II study of triapine in combination with gemcitabine in advanced pancreatic carcinoma: A Princess Margaret Hospital phase II consortium trial. Conferences
- A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] phase II consortium. Conferences
- A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs). Conferences
- Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen. Conferences
- Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer (ACRC) Conferences
- Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures. Conferences
- HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial. Conferences
- Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents Conferences
- Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. Conferences
- Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors. Conferences
- Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium. Conferences
- Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma. Conferences
- Pre-radiation R115777 in patients with newly diagnosed glioblastoma multiforme and residual enhancing disease Conferences
- Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib. Conferences
- Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Conferences
- Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Conferences
- S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results Conferences
- S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. Conferences
- The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases. Conferences
- The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents. Conferences
- What are the supportive care service needs of recently diagnosed cancer patients? Results of a population based study Conferences
- Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual. Conferences